David Einhorn Gain Therapeutics, Inc. Transaction History
Greenlight Capital Inc
- $1.97 Billion
- Q4 2023
A detailed history of David Einhorn (Greenlight Capital Inc) transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Greenlight Capital Inc holds 588,410 shares of GANX stock, worth $764,933. This represents 0.1% of its overall portfolio holdings.
Number of Shares
588,410
Previous 546,560
7.66%
Holding current value
$764,933
Previous $2.45 Million
21.41%
% of portfolio
0.1%
Previous 0.12%
Shares
2 transactions
Others Institutions Holding GANX
# of Institutions
33Shares Held
2.58MCall Options Held
22.2KPut Options Held
16K-
Dme Capital Management, LP New York, NY566KShares$735,9690.1% of portfolio
-
Raymond James & Associates St Petersburg, FL260KShares$338,0240.0% of portfolio
-
Royal Bank Of Canada Toronto, A6249KShares$323,0500.0% of portfolio
-
Geode Capital Management, LLC Boston, MA177KShares$230,2180.0% of portfolio
-
Telemetry Investments, L.L.C. New York, NY123KShares$159,9000.61% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $15.4M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...